Increasing the dose of secukinumab in suboptimal responders: a possible therapeutic strategy

Ital J Dermatol Venerol. 2022 Apr;157(2):195-196. doi: 10.23736/S2784-8671.21.06931-5. Epub 2021 Apr 23.

Authors

Federico Bardazzi¹, Diego Abbenante², Lidia Sacchelli¹, Annalisa Patrizi¹, Camilla Loi¹

Affiliations

¹ Department of Dermatology, IRCCS Policlinico di Sant'Orsola, Bologna, Italy.
² Department of Dermatology, IRCCS Policlinico di Sant'Orsola, Bologna, Italy - diego.abbenante@studio.unibo.it.

PMID: 33890742
DOI: 10.23736/S2784-8671.21.06931-5

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Humans
Psoriasis* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
secukinumab